Drug intelligence / Profile preview

miR-143 inhibitor

Development stage
Preclinical
Lead developer
University of Puerto Rico
Modality
Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intratumoral, Intralesional
01

Overview

miR-143 inhibitor refers to a class of antisense oligonucleotides designed to specifically bind to and sequester microRNA-143 (miR-143), thereby preventing it from regulating its target messenger RNAs. In the context of oncology, particularly glioblastoma multiforme (GBM), miR-143 has been observed to be overexpressed in patient samples. While *in vitro* studies using miR-143 inhibitors have shown reduced cell proliferation and increased apoptosis in GBM cell lines, some *in vivo* studies have reported paradoxical increases in tumor growth, suggesting complex roles for miR-143 within the tumor microenvironment. These inhibitors are typically formulated in delivery vehicles such as liposomes to enhance stability and cellular uptake.

Other names
anti-miR-143anti-miR143anti-miR 143microRNA-143 inhibitormicroRNA143 inhibitormicroRNA 143 inhibitorantagomir-143antagomir143antagomir 143
02

Targets

miR-143-3p (MicroRNA 143-3p)

Beyond the preview

Go deeper on miR-143 inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on miR-143 inhibitor.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call